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Interferon regulatory factor (IRF)-3 is a master transcription factor that activates host antiviral defense programs.
Although cell culture studies suggest that IRF-3 promotes antiviral control by inducing interferon (IFN)-b, near normal
levels of IFN-a and IFN-b were observed in IRF-3/ mice after infection by several RNA and DNA viruses. Thus, the
specific mechanisms by which IRF-3 modulates viral infection remain controversial. Some of this disparity could reflect
direct IRF-3-dependent antiviral responses in specific cell types to control infection. To address this and determine how
IRF-3 coordinates an antiviral response, we infected IRF-3/ mice and two primary cells relevant for West Nile virus
(WNV) pathogenesis, macrophages and cortical neurons. IRF-3/ mice were uniformly vulnerable to infection and
developed elevated WNV burdens in peripheral and central nervous system tissues, though peripheral IFN responses
were largely normal. Whereas wild-type macrophages basally expressed key host defense molecules, including RIG-I,
MDA5, ISG54, and ISG56, and restricted WNV infection, IRF-3/ macrophages lacked basal expression of these host
defense genes and supported increased WNV infection and IFN-a and IFN-b production. In contrast, wild-type cortical
neurons were highly permissive to WNV and did not basally express RIG-I, MDA5, ISG54, and ISG56. IRF-3/ neurons
lacked induction of host defense genes and had blunted IFN-a and IFN-b production, yet exhibited only modestly
increased viral titers. Collectively, our data suggest that cell-specific IRF-3 responses protect against WNV infection
through both IFN-dependent and -independent programs.
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Introduction
West Nile virus (WNV) is a mosquito-borne, positive
polarity, single-stranded RNA virus in the Flaviviridae
family. In humans, WNV causes a spectrum of illness that
ranges from a self-limiting WNV fever to ﬂaccid paralysis
and fatal encephalitis [1]. WNV is endemic in Africa, Europe,
Asia, and Australia, and has emerged in the Western
hemisphere with annual outbreaks in North America; addi-
tionally, WNV has recently spread to Mexico and Central
and South America.
Rodent models have helped to elucidate the mechanisms of
WNV dissemination and pathogenesis. Following mosquito
inoculation, WNV replicates in Langerhans and other naive
dendritic cells in the skin [2,3]. WNV then spreads to the
draining lymph nodes and spleen, where viral ampliﬁcation
occurs in subsets of CD11bþ myeloid cells [4]. Virus
subsequently disseminates to the central nervous system
(CNS) and infects neurons [5,6]. Innate and adaptive immune
responses are required for control and clearance of WNV
infection (reviewed in [7]). Induction of interferon (IFN)-a
and IFN-b genes is essential to the host response against viral
infections, including WNV [8–10]. Mice lacking the IFN-a and
IFN-b receptor (IFN-a/bR/) were extremely susceptible to
WNV infection, with expanded viral tropism in myeloid cells,
early dissemination in the CNS, uncontrolled viral replica-
tion, and early and uniform death.
Studies by several groups have begun to deﬁne the
molecular mechanisms by which immune and nonimmune
cells detect and respond to RNA viruses (reviewed in [11,12]).
Binding of single-stranded or double-stranded viral RNA to
retinoic acid–inducible gene (RIG)-I, melanoma differentia-
tion antigen (MDA)5, Toll-like receptor (TLR)3, TLR7, or
TLR8 results in downstream activation of transcription
factors, such as interferon regulatory factors 3 and 7 (IRF-3
and IRF-7), production of IFN-a and IFN-b, and the
expression of IFN-stimulated genes (ISGs).
An emerging literature suggests that RIG-I and IRF-3 have
essential functions in the response to WNV infection. Murine
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embryonic ﬁbroblasts (MEFs) deﬁcient in RIG-I have a
delayed host defense response, decreased IRF-3 activation,
and augmented WNV replication [13,14]. In contrast, MDA5
and TLR3, pathogen recognition receptors that also signal
through IRF-3, may be less essential for ﬂavivirus recognition
and control. No distinct in vivo phenotype was observed in
MDA5/ mice after infection with the closely related
ﬂavivirus, Japanese encephalitis virus [15]. TLR3 may be
dispensable for recognition of WNV in some cell types in
vitro [13,16] and in vivo [17], as only small differences in viral
yield were observed in the absence of TLR3.
Induction of an optimal IFN response after RNA virus
infection likely requires signaling through both IRF-3 and
IRF-7 [18–21]. IRF-3/ mice are more susceptible to
encephalomyocarditis virus (EMCV), and IRF-3/ MEFs
exhibited a reduced capacity to produce IFN after infection
with several RNA and DNA viruses, including Newcastle
disease virus, herpes simplex virus (HSV), vesicular stomatitis
virus (VSV), and EMCV [19,22]. Nonetheless, others have
reported that IRF-3 is not required for IFN production in
dendritic cells after RNA virus infection (VSV, EMCV), and
serum levels of IFN-a and IFN-b after HSV, EMCV, and
Semliki Forest virus (SFV) infection in IRF-3/ mice did not
differ substantially from those of congenic wild-type controls
[22,23]. The role of IRF-3 in regulating the basal expression of
host defense genes, inducing IFN, and promoting an antiviral
response in different primary cell types with a given virus
remains unknown.
We evaluated the function of the master transcriptional
regulator IRF-3 in vivo and ex vivo in cell types relevant to
WNV pathogenesis. Mice lacking IRF-3 were acutely vulner-
able to WNV infection with uniform mortality. IRF-3 was
essential for controlling WNV replication in peripheral
tissues and myeloid cells through largely IFN-independent
pathways. Moreover, in cortical neurons, IRF-3 had a smaller
antiviral function, yet regulated production of IFN-a and
IFN-b. These data suggest that cell-speciﬁc IRF-3 responses
protect against WNV infection through both IFN-dependent
and -independent mechanisms.
Results
IRF-3 Is Required for Controlling Lethal WNV Infection
Mice lacking IFN-a and IFN-b receptors are extremely
vulnerable to WNV infection due to rapid and overwhelming
viral replication [9,24]. To dissect the mechanisms regulating
IFN induction after WNV infection in vivo, we evaluated the
effect of a genetic deﬁciency of IRF-3, a known regulator of
IFN induction, on survival. After footpad inoculation with 102
PFU of WNV, IRF-3/ mice showed an increased rate and
severity of acute clinical symptoms, including hunchback
posture, weight loss, fur rufﬂing, and reduced activity. IRF-3/
mice were signiﬁcantly more vulnerable to lethal WNV
infection, with a 0% survival rate and a mean time to death
of 9.3 6 1.1 days compared to wild-type mice, which had a
65% survival rate and a mean time to death of 10.7 6 1.6 (p ,
0.0001, Figure 1A). Thus, signaling through IRF-3 is essential
for protecting mice against lethal WNV infection.
IRF-3/ Mice Have Enhanced WNV Replication
Because IFN has an essential role in controlling WNV
dissemination, we hypothesized that a deﬁciency of IRF-3
would result in higher tissue viral burdens. To evaluate this,
IRF-3/ and wild-type mice were infected with 102 PFU of
WNV via a footpad route, and viral burden was measured by
ﬂuorogenic quantitative reverse transcriptase polymerase
chain reaction (qRT-PCR) or viral plaque assay at days 1, 2,
4, 6, 8, and 10 post infection in blood, peripheral organs
(draining lymph nodes, spleen, and kidney), and the CNS
(brain and spinal cord).
Blood and lymph node. In the absence of IRF-3, signiﬁ-
cantly higher levels of viral RNA were observed by days 2 and
4 after infection in serum (10.6-fold, p , 0.0001; and 4.8-fold,
p , 0.0001; Figure 1B) and draining popliteal lymph nodes
(2.2-fold, p¼ 0.03; and 5.3-fold, p¼ 0.02; Figure 1C). At day 6,
viremia in wild-type mice declined, whereas WNV RNA levels
remained elevated in IRF-3/ mice (p , 0.005).
Spleen and kidney. In wild-type mice, infectious virus was
not detected in the spleen by plaque assay at day 2 after
infection (n ¼ 10). In contrast, 100% (10 of 10) of IRF-3/
mice had measurable infection at day 2 (average titer 103.1
PFU/g, p , 0.0001) (Figure 1D). Increased WNV was also
observed in IRF-3/ mice at day 4 (average titer 104.6 PFU/g
versus 103.6 PFU/g for wild type, p ¼ 0.003), which corre-
sponded to the peak of infection in both groups. High levels
of infectious WNV (average titer 103.7 PFU/g, p, 0.0001) were
still detectable at day 6 in all (10 of 10) IRF-3/ mice. In
contrast, WNV was cleared from the spleen in the majority (7
of 10) of wild-type mice at this time, with remaining animals
having lower viral burdens. By day 8, WNV was largely cleared
from the spleen of IRF-3/ and wild-type mice.
Little or no replication occurs in the kidney after
peripheral WNV infection of wild-type C57BL/6 mice. In
contrast, ;106 PFU/g of WNV was observed in the kidneys of
IFN-a/bR/ mice [9], which indicates a role for IFN in
restricting tissue tropism. Signiﬁcant WNV infection was also
observed in the kidney of IRF-3/mice (day 6, 102.8 PFU/g, p
, 0.05; day 8, 103.2 PFU/g, p , 0.005; Figure 1E). Based on
virologic data from the serum, lymph node, spleen, and
kidney, IRF-3 signaling modulates WNV infection in periph-
eral tissues and functions to restrict tissue tropism.
CNS. WNV spread more rapidly and replicated to higher
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Author Summary
West Nile virus (WNV) is a mosquito-transmitted RNA virus that
infects birds, horses, and humans, and it has become an emerging
infectious disease threat in the Western hemisphere, including all of
the continental United States. WNV invades the brain and spinal
cord and infects and injures neurons, causing severe neurological
disease, including encephalitis and paralysis, primarily in the
immunocompromised and elderly. An increased understanding of
how the immune system recognizes WNV and promotes an antiviral
defense is vital to developing novel therapeutics and vaccines that
limit disease, and identifying individuals at high risk for severe
disease. In this study, using a mouse model of WNV pathogenesis,
we evaluate the functional role of interferon regulatory factor 3 (IRF-
3), a master transcriptional regulator of interferon induction and
antiviral responses, in controlling infection. Mice that lack IRF-3 were
uniformly susceptible to severe infection with 100% lethality. We
observed cell-type–specific responses, as neurons and macrophages
utilized IRF-3 to protect against WNV infection through distinct
antiviral pathways. Finally, IRF-3 also appears to regulate the basal
expression of specific sensors of viral infection, which in turn affects
the antiviral state of a cell prior to virus entry.
levels in the CNS of IRF-3/ mice. Infectious WNV was
present in the brains of IRF-3/mice (9 of 10) at day 4 after
infection, whereas in wild-type mice, WNV was not detected
until day 6. IRF-3/ mice also averaged signiﬁcantly higher
viral titers than wild-type mice in the brain on days 6, 8, and
10 after infection (20-fold, p , 0.0001; ;200-fold, p , 0.0001;
and 10-fold, p , 0.005, respectively), which corresponded
with increased morbidity and mortality (Figure 1F). A similar
pattern was observed in the spinal cord, where earlier entry
was observed in IRF-3/ mice with 60% (6 of 10) having
detectable viral loads at day 6 in contrast to 0% (0 of 10) of
wild-type mice. Moreover, higher viral burden was also
Figure 1. Survival and Virologic Analysis for Wild-Type and IRF-3/ C57BL/6 Mice
(A) Eight- to twelve-week-old mice were inoculated with 102 PFU of WNV by footpad injection and followed for mortality for 21 d. Survival differences
were statistically significant (n ¼ 20, IRF-3/; and n¼ 20, wild-type mice; p , 0.0001).
(B–G) Viral burden in peripheral and CNS tissues after WNV infection. WNV RNA in (B) serum and (C) draining lymph node, and infectious virus in the (D)
spleen, (E) kidney, (F) brain, and (G) spinal cord were determined from samples harvested on days 1, 2, 4, 6, 8, and 10 using qRT-PCR (B, C) or viral plaque
assay (D–G). Data is shown as viral RNA equivalents or PFU per gram of tissue for ten to 12 mice per time point. For all viral load data, the solid line
represents the median PFU per gram at the indicated time point, and the dotted line represents the limit of sensitivity of the assay. Error bars indicate
the standard deviations (SD). Asterisks indicate values that are statistically significant (*, p , 0.05; **, p , 0.005; ***, p , 0.0001) compared to wild-type
mice.
doi:10.1371/journal.ppat.0030106.g001
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observed in the spinal cord of IRF-3/mice at days 8 and 10,
with ;220-fold (p , 0.0001) and ;10-fold (p , 0.005)
increased titers compared to wild-type mice, respectively
(Figure 1G). Overall, an absence of IRF-3 signaling led to
increased WNV infection in peripheral tissues, resulting in
early spread and increased replication in the CNS.
Production of WNV-Specific IgM and IgG Antibodies in
IRF-3/ Mice
IFN-a and IFN-b are immunomodulatory cytokines with
speciﬁc roles in priming adaptive immune responses [25].
Because a higher viremia was observed in mice that lacked
IRF-3, we reasoned that this could be due to depressed WNV-
speciﬁc antibody responses. Interestingly, higher rather than
lower titers of WNV-speciﬁc IgM and IgG were detected in
IRF-3/ mice (unpublished data), possibly secondary to the
increased viral burden in the lymph node and spleen. Because
WNV-speciﬁc antibody responses were not blunted in IRF-3/
mice, it is likely that the increased infection in the periphery
was not due to inadequate priming of B cell responses.
IRF-3 Has a Small and Transient Effect on IFN-a and IFN-b
Gene Induction in Draining Lymph Nodes
In vitro studies suggest that recognition of double-stranded
RNA viruses by RIG-I, MDA5, and/or TLR3 results in IRF-3-
dependent transcription of IFN-b and other ISGs [15,26,27].
Nonetheless, studies in mice with EMCV, SFV, and HSV have
shown that an absence of IRF-3 does not substantially alter
systemic production of IFN-a and IFN-b, presumably because
of signaling redundancies. To directly test the role of IRF-3
on IFN induction soon after WNV infection in vivo, we
measured levels of IFN-a and IFN-b mRNAs in the draining
lymph nodes of WNV-infected mice. In wild-type mice, IFN-a
and IFN-b mRNA levels were induced within 24 h of WNV
infection (;2-fold increase for IFN-a and 3-fold increase for
IFN-b). By 48 h and 96 h post infection, IFN-a and IFN-b
tissue mRNA levels increased ;5-fold and ;7-fold, respec-
tively (Figure 2A). In IRF-3/mice, the induction of the IFN-a
and IFN-b genes at 24 h was comparable to levels found in
wild-type mice. However, at 48 h, there was a small yet
statistically signiﬁcant decrease in IFN gene induction in the
draining lymph nodes of IRF-3/ mice compared to that of
wild-type mice (IFN-a, n¼15, p¼0.009; IFN-b, n¼12, p¼0.05;
Figure 2B). By 96 h after infection, the induction of IFN-a and
IFN-b genes was similar to that observed in wild-type mice.
Thus, a deﬁciency of IRF-3 in vivo had a small and transient
effect on early IFN gene induction in lymphoid tissues after
infection with WNV.
Systemic Levels of IFN-a and IFN-b Are Similar in IRF-3/
and Wild-Type Mice
As the absence of IRF-3 partially modulated IFN gene
induction in the lymph node, we hypothesized that the
virologic phenotype observed in IRF-3/ mice could be due
to depressed levels of IFN-a and IFN-b in circulation. To
evaluate this, IRF-3/ and wild-type mice were infected with
WNV, and the presence of biologically active IFN in serum
was monitored using a previously validated EMCV-L929 cell
bioassay [4,28]. IFN activity in the serum of infected wild-type
mice was detected at 24 h, peaked at 72 h, and then decreased
at 96 h (Figure 2C). Somewhat surprisingly, IFN activity in the
WNV-infected IRF-3/ mice was equivalent to or greater
than that observed in wild-type mice. For example, 2.5-fold
higher levels of IFN activity were observed in IRF-3/mice at
48 h after infection (p , 0.0001). This data is consistent with
previous studies with EMCV and HSV [22] in which a
deﬁciency of IRF-3 did not signiﬁcantly diminish systemic
accumulation of IFN.
Effect of IRF-3 on WNV Infection and IFN Induction in
Macrophages
Although the IRF-3/ mice showed signiﬁcant virologic
and mortality phenotypes, small differences were observed in
IFN-a and IFN-b gene induction and antiviral activity in the
lymph node and intravascular compartments. Because IRF-3
can also directly induce IFN-stimulated antiviral genes in an
Figure 2. IFN Induction in Draining Lymph Nodes and Serum of Mice Infected with WNV
(A, B) Mice were inoculated with 102 PFU of WNV by footpad injection and euthanized at the indicated times. Total RNA from draining lymph was
analyzed for (A) IFN-a and (B) IFN-b mRNA expression by qRT-PCR. Data are normalized to 18S rRNA and are expressed as the relative fold increase over
normalized RNA from uninfected controls. Average values are from five to 12 mice per time point, and error bars indicate the SD. Asterisks indicate
differences that are statistically significant (*, p , 0.05).
(C) IFN activity was determined from serum collected on days 1 to 4 after infection by an EMCV bioassay in L929 cells. Data reflect the average of serum
samples harvested from five to ten mice per time point and are shown as the percentage of cells protected from lysis by EMCV (see Materials and
Methods). Asterisks indicate differences that are statistically significant (*, p , 0.05; ***, p , 0.0001).
doi:10.1371/journal.ppat.0030106.g002
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IFN-independent manner [29–31], we hypothesized that some
of its inhibitory functions against WNV could be direct and
independent of IFN. To address this question, we isolated
resting macrophages from wild-type and IRF-3/ mice and
performed virologic and protein expression analyses. Macro-
phages were chosen for study because subsets of these cells
are infected in vivo by WNV [4].
Increased WNV replication was observed in IRF-3/
macrophages beginning at 24 h after infection (Figure 3).
An absence of IRF-3 resulted in a 16-fold, 26-fold, and 5-fold
increase in viral titers at 24, 48, and 72 h, respectively (p ,
0.002; Figure 3A). To determine whether the increased
infection in IRF-3/ macrophages was due to altered IFN
levels, we analyzed the kinetics of IFN-a and IFN-b
production in WNV-infected wild-type and IRF-3/ cells.
Paradoxically, earlier and higher levels of IFN-a and IFN-b
mRNA induction were observed in WNV-infected IRF-3/
macrophages (Figure 3B). Consistent with this, at 48 and 72 h,
higher levels of IFN-a and IFN-b were observed in super-
natants from WNV-infected IRF-3/ cells (Figure 3C and 3D).
We hypothesize that this increased IFN production is
secondary to the signiﬁcantly increased viral infection in
IRF-3/ cells. To determine whether other transcriptional
regulators that induce IFN gene expression could be
compensating for a deﬁciency of IRF-3, we analyzed
induction of IRF-5 and IRF-7 after WNV infection. Notably,
IRF-7 levels were ;2.5 and ;5-fold higher (p , 0.05; Figure
3E) in IRF-3/ macrophages at 24 and 48 h after WNV
infection, respectively. In contrast, no difference in IRF-5
levels was observed (unpublished data). Thus, in primary
macrophages, induction of IFN-a and IFN-b after WNV
infection is IRF-3-independent and likely IRF-7-dependent.
Moreover, in these cells, IRF-3 restricts WNV replication
independently of IFN.
As IRF-3 did not modulate IFN production during WNV
infection, we evaluated its role in directly inducing expres-
sion of ISGs; some ISGs have antiviral activity and could
contribute to differences in viral growth curves. ISG54 and
Figure 3. IRF-3 Modulates WNV Infection in Primary Macrophages
(A) Macrophages generated from wild-type or IRF-3/mice were infected at an MOI of 0.01, and virus production was evaluated at the indicated times
post infection by plaque assay. Values are an average of quadruplicate samples generated from at least three independent experiments. Error bars
represent the SD, and asterisks indicate differences that are statistically significant relative to wild-type mice (*, p , 0.05; **, p , 0.005; ***, p , 0.0001).
(B) The induction of IFN-a and IFN-b mRNA in WNV-infected macrophages was analyzed by qRT-PCR as described in Figure 2.
(C, D) Accumulation of IFN-a (C) and IFN-b (D) protein in supernatants of WNV-infected macrophages was determined by ELISA. The data is the average
of at least five independent experiments performed in triplicate. *, p , 0.05.
(E) The induction of IRF-7 mRNA in WNV-infected macrophages was analyzed by qRT-PCR as described in Figure 2. *, p , 0.05.
doi:10.1371/journal.ppat.0030106.g003
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ISG56 are IRF-3 target genes that inhibit translation
[29,30,32] and are up-regulated in WNV-infected MEFs [14].
Thus, we assessed the expression of ISG54 by Western blot
and ISG56 by qRT-PCR in macrophages (Figure 4A and 4B).
Basal expression of ISG54 and ISG56 was observed in wild-
type but not in IRF-3/ cells. However, infection with WNV
or pretreatment with IFN-b (100 IU/ml) induced ISG54 and
ISG56 expression in both wild-type and IRF-3/ cells (Figure
4A and unpublished data). Thus, ISG54 and ISG56 are basally
expressed in primary macrophages in an IRF-3-dependent
manner, yet induced through an IRF-3-independent and IFN-
dependent pathway.
Since the basal levels of ISG54 and ISG56 were lower in
IRF-3/ compared to wild-type macrophages, we speculated
that IRF-3 might also indirectly affect the levels of the
cytosolic double-stranded viral RNA sensors (RIG-I and
MDA5). Basal expression of RIG-I and MDA5 was present in
wild-type macrophages, but noticeably lower in IRF-3/ cells
(Figure 4C). After WNV infection, RIG-I and MDA5 were
induced in an IRF-3-independent manner in macrophages.
Overall, these experiments suggest that macrophages, because
of their IRF-3-dependent basal expression of RIG-I, MDA5,
and speciﬁc ISG, are poised to detect cytoplasmic viral RNA
and generate an early host response that limits viral
replication.
Effect of IRF-3 on the Control of Neuronal Infection
Mice deﬁcient in IRF-3 showed increased WNV burden in
the brain and spinal cord after peripheral infection. This
phenotype could be due either to increased dissemination
from the periphery and/or an independent antiviral effect in
the CNS. To test this, wild-type and IRF-3/ mice were
infected with 101 PFU of WNV via an intracranial (IC) route
and survival was monitored (Table 1). Both groups of mice
showed rapid and complete mortality following IC infection,
though IRF-3/ mice showed a slight but signiﬁcantly
decreased average survival time relative to wild-type mice
(mean time to death of 6.5 and 7.2 for the IRF-3/ and the
wild-type mice, respectively, p ¼ 0.003). These data suggest
that IRF-3 has a subtle yet independent function in
protection against WNV in the CNS. To further examine
the role of IRF-3 in the CNS, we measured viral burden in the
brain and spinal cord on days 4 and 6 after IC inoculation.
IRF-3/ animals had signiﬁcantly higher mean viral burdens
at day 4 after infection in brain (107.6 PFU/g for IRF-3/ and
105.7 PFU/g for wild-type, p¼ 0.02) and spinal cord (105.7 PFU/
g for IRF-3/ and 104.0 PFU/g for wild-type, p¼ 0.008). By day
6 after infection, no signiﬁcant differences in viral titers were
observed between wild-type and IRF-3/mice (p . 0.3 and p
. 0.7 in brain and spinal cord, respectively).
Effect of IRF-3 on WNV Infection and IFN Induction in
Primary Cortical Neurons
Production of type I IFN by neurons has been observed
after infection of other RNA viruses and could serve an
antiviral role in vivo [33,34]. To evaluate whether IRF-3
directly modulates neuronal infection or IFN production, we
generated primary cortical neuron cultures [35,36] from wild-
Figure 4. The Effect of IRF-3 on ISG54, ISG56, RIG-I, and MDA5 Expression
in Macrophages
(A) Whole cell lysates were generated at the indicated times from wild-
type or IRF-3/ macrophages that were uninfected (U), infected with
WNV (W), or pretreated with 100 IU/ml of IFN-b (Pre). Protein levels of
ISG54 and GAPDH were examined by immunoblot analysis.
(B) Total RNA was harvested from WNV-infected macrophages and mRNA
levels of ISG56 were quantified by qRT-PCR as described in Figure 2. Data
are expressed as relative fold induction over uninfected IRF-3/ cells.
Asterisks indicate differences that are statistically significant (**, p ,
0.005).
(C) Whole cell lysates were generated at the indicated times from wild-
type or IRF-3/ macrophages that were uninfected (U) or infected with
WNV (W) for 12 or 24 h. Protein levels of RIG-I, MDA5, and GAPDH were
examined by immunoblot analysis
doi:10.1371/journal.ppat.0030106.g004
Table 1. Survival of Wild-Type and IRF-3/ C57BL/6 Mice
following IC Inoculation
Genotype Survival Rate Mean Time to Death (Days) p-Value
Wild-type 0/48 7.2 6 1.1
IRF-3/ 0/18 6.5 6 0.6 p ¼ 0.003
C57BL/6 wild-type and IRF-3/ mice were inoculated by an intracranial route with 101
PFU of WNV and monitored for survival.
doi:10.1371/journal.ppat.0030106.t001
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type and IRF-3/ mice. Neurons in the cerebral cortex are
targets of WNV infection [6], can be generated with high
purity (;98%–99%), and are acutely susceptible to WNV
infection in vitro [36].
Wild-type neurons were signiﬁcantly more permissive to
WNV infection than macrophages: infection with 10-fold less
virus (multiplicity of infection [MOI] 0.001 versus 0.01)
produced ;560-fold more virus within 48 h (p , 0.0001)
(Figures 3A and Figure 5A). Multi-step growth curve analysis
of wild-type and IRF-3/ cortical neurons showed no differ-
ence at 24 h and only a small (5-fold, p ¼ 0.005) increase in
WNV infection in the absence of IRF-3 at 48 h (Figure 5A).
Unlike macrophages, cortical neurons required IRF-3 for
efﬁcient IFN production, as decreased levels of IFN-a (at 48 h,
6.8-fold, p¼ 0.02; 72 h, 4.7-fold, p¼ 0.02) and IFN-b (24 h, 7.5-
fold, p¼ 0.001; 48 h, 3.6-fold, p¼ 0.04; and 72 h, 2.9-fold, p¼
0.009) were detected in the supernatants of WNV-infected
IRF-3/ neurons (Figure 5C and 5D). Kinetic analysis of IFN
gene induction also showed markedly higher (12- to 55-fold)
IFN-b levels compared to IFN-a levels at 24 to 48 h after
infection in wild-type neurons and blunted IFN transcript
levels in WNV-infected IRF-3/ neurons (Figure 5B). As IFN
pretreatment inhibits WNV infection in cortical neurons a
maximum of 5- to 8-fold [4], the modest viral replication
phenotype in IRF-3/ neurons is consistent with the
decreased IFN production by these cells. To determine
whether the IFN phenotype in IRF-3/ neurons was
associated with altered expression of other IFN transcrip-
tional regulators, we analyzed the induction of IRF-7.
Notably, IRF-7 mRNA levels were ;25- and ;5-fold lower
(p , 0.05; Figure 5E) in IRF-3/ neurons at 24 and 48 h after
WNV infection, respectively. Thus, the defect of IFN-
production in IRF-3/ cortical neurons may occur because
of blunted IRF-7 induction.
To further explore the function of IRF-3 in antiviral
signaling pathways in cortical neurons, we assessed the levels
Figure 5. WNV Infection and IFN Production in Primary Cortical Neurons
(A) Primary cortical neurons generated from wild-type or IRF-3/ mice were infected at an MOI of 0.001, and virus production was evaluated at the
indicated times by plaque assay. Values are an average of triplicate samples generated from three independent experiments, error bars represent the
SD, and asterisks indicate values that are statistically significant (**, p , 0.005).
(B–D) The induction of IFN-a and IFN-b mRNA in WNV-infected primary cortical neurons. IFN mRNA was analyzed by qRT-PCR as described in Figure 2.
(C) IFN-a and (D) IFN-b protein accumulation in supernatants of WNV-infected cortical neurons from wild-type and IRF-3/ mice was measured by
ELISA.
(E) The induction of IRF-7 mRNA in WNV-infected primary cortical neurons was analyzed by qRT-PCR as described in Figure 2.
(B–E) Data are the average of three independent experiments performed in duplicate, and the asterisks indicate statistically significant differences (*, p
, 0.05; **, p , 0.005, ***, p , 0.0001).
doi:10.1371/journal.ppat.0030106.g005
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of ISG54 and ISG56 (Figure 6A and 6B). Unlike macrophages,
ISG54 and ISG56 were not expressed basally in uninfected
wild-type cortical neurons. Also, in contrast to macrophages,
a deﬁciency of IRF-3 abolished production of ISG54 and
ISG56 in neurons after WNV infection. Nonetheless, pre-
treatment with IFN-b (100 IU/ml) strongly induced ISG54 and
ISG56 in wild-type and IRF-3/ neurons. Taken together,
these results suggest that IRF-3 is required in cortical neurons
both for optimal induction of antiviral ISGs and IFN
production after WNV infection. Surprisingly, RIG-I and
MDA-5 were not basally expressed in wild-type or IRF-3/
cortical neurons but were induced in an IRF-3-dependent
fashion at 24 and 48 h after infection (Figure 6B). Thus, in
cortical neurons, the intracellular viral RNA sensors RIG-I
and MDA5 are absent when WNV enters the cytoplasm but
are induced after infection through an IRF-3-dependent
mechanism.
Discussion
An intact type I IFN response controls WNV infection in
mice and limits replication in speciﬁc cell populations [9]. In
vitro studies in MEFs suggested that the host response
restricts WNV spread, in part, through activation of the
IRF-3 pathway [14]. In this study, we established IRF-3 as an
essential regulator of the early host response in vivo after
WNV infection. Mice lacking IRF-3 were uniformly vulner-
able with increased viremia, higher viral burden in peripheral
tissues, altered tissue tropism, and earlier entry into the CNS.
Ex vivo studies showed that speciﬁc primary cell types utilize
IRF-3 with distinct functional consequences: in macrophages,
IRF-3 was required for basal ISG expression and control of
WNV infection, whereas in neurons, IRF-3 was necessary for
efﬁcient IFN induction. Remarkably, in vitro studies in
myeloid cells and in vivo experiments suggested that a
deﬁciency of IRF-3 did not dramatically diminish the
peripheral IFN response to WNV infection, yet was still
required for early control of WNV replication and spread.
Thus, IRF-3 plays distinct roles in diverse cell types to limit
WNV through IFN-dependent and -independent mecha-
nisms.
Host pathogen recognition receptors sense RNA viruses
and direct an early host response through IRF activation and
the induction of IFN-b and ISGs. For example, RIG-I, MDA5,
and TLR3 all recognize double-stranded viral RNA and signal
through IRF-3 [15,26,27]. Although IRF-3 plays a key role in
limiting WNV infection in vitro in MEFs [14], its function in
triggering host defense responses after WNV infection in vivo
in cell types relevant to pathogenesis was unknown. Our
experiments demonstrate that IRF-3 is absolutely required
for the immediate control of WNV replication in vivo:
increased viral burden and uniform death were observed in
IRF-3/ mice within 10 d of peripheral WNV infection. The
increased level of WNV in IRF-3/ mice did not correlate
with signiﬁcant effects on systemic production of IFN-a and
IFN-b; these results are consistent with studies of EMCV,
HSV, and SFV infection of IRF-3/mice [22,23]. This suggests
that the protective effect of IRF-3 is largely independent of
the production of IFN-a and IFN-b in the periphery, and
instead is due likely to the antiviral actions of speciﬁc IRF-3
target genes. However, similar to IFN-a/bR/ mice [9], WNV
infection of IRF-3/ mice also resulted in altered tissue
tropism. Analysis of the cellular basis of expanded tropism in
IFN-a/bR/mice showed increased infection of macrophages
[9]. As a deﬁciency of IRF-3 in macrophages ex vivo
signiﬁcantly altered basal expression of key host defense
molecules, the expanded in vivo tropism in IRF-3/mice may
be due, in part, to enhanced infection in normally resistant
tissue macrophages.
Although it is not known which pathogen recognition
receptor contributes to the recognition of WNV in vivo, RIG-
I is a likely candidate. TLR3/ mice showed only moderately
increased WNV infection in peripheral tissues [17], and
MDA5/ mice showed no difference in susceptibility com-
pared to wild-type mice with the closely (;90% amino acid
identity) related ﬂavivirus, Japanese encephalitis virus. In
contrast, RIG-I/ mice were highly vulnerable to Japanese
encephalitis virus infection, with 100% mortality after 7 d
[15]. Further studies are required to evaluate the relative role
of different pathogen recognition receptors in sensing WNV
and inducing an antiviral response.
IRF-3 appeared to exert its antiviral activity by modulating
the antiviral state of individual cell types. Our results in IRF-
3/ macrophages agree with studies of IRF-3/ splenic
dendritic cells, which showed relatively normal IFN induction
after infection with VSV or HSV [22]. However, they contrast
Figure 6. The Effect of IRF-3 on ISG54, ISG56, RIG-I, and MDA5 Expression
in WNV-Infected Cortical Neurons
(A, B) Whole cell lysates were generated at the indicated times from wild-
type or IRF-3/ primary cortical neurons. These neurons were uninfected
(U), infected with WNV (W), pretreated with 100 IU/ml of IFN-b (Pre), or
treated with IFN after infection (P/W). (A) ISG54 immunoblot analysis and
figure labeling is as described in Figure 4. (B) Protein levels of IRF-3, RIG-I,
MDA5, ISG56, WNV, and GAPDH were examined by immunoblot analysis
as described in Materials and Methods.
doi:10.1371/journal.ppat.0030106.g006
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with studies of MEFs or myeloid dendritic cells whereby IRF-3
was required to fully activate IFN-a and IFN-b responses after
infection with HSV, VSV, EMCV [19,22], or SFV [23]. These
latter results are more consistent with our cortical neuron
data, in which induction of IFN-a and IFN-b was regulated, in
part, by an IRF-3-dependent mechanism. We propose a
model in which the activation of IFN genes after virus
recognition in different cells is mediated by IRF-3-dependent
and -independent pathways. Although IRF-7 is an obvious
candidate for the IRF-3-independent pathway, [37], other IRF
family members could regulate IFN gene expression. IRF-5
and IRF-8 have been implicated in IFN gene induction in
macrophages and dendritic cells after Newcastle disease virus
and Sendai virus infection [38–40]. Our preliminary data
suggest that IRF-7 may have a dominant role in IFN
induction: IRF-3/ macrophages that had no defect in IFN
production showed strong induction of IRF-7 mRNA after
WNV infection. In contrast, IRF-3/ cortical neurons, which
had blunted production of IFN, also had markedly lower
levels of IRF-7 mRNA after infection. Clearly, additional
studies are required to establish the precise cell-speciﬁc
regulatory pathways for IFN induction after WNV and other
viral infections.
IRF-3 has been previously shown to contribute to an
antiviral state by activating ISGs, including ISG54 and ISG56,
in an IFN-dependent and -independent manner in ﬁbroblasts
and epithelial cells infected with HSV, VSV, Newcastle
disease, vaccinia, and Sendai viruses [31]. When we examined
the expression of ISG54 and ISG56, genes that are directly
regulated by IRF-3 [30], activated after WNV infection [14],
and have antiviral activity [29], we found that ISG54 and
ISG56 were basally expressed in macrophages in an IRF-3-
dependent manner. Similar ﬁndings were observed for the
intracellular double-stranded RNA sensors MDA5 and RIG-I.
However, after WNV infection or pretreatment with IFN-b,
ISG54, ISG56, and RIG-I induction occurred independently
of IRF-3. Thus, the levels of these host defense genes in
myeloid cells are modulated both by IRF-3 and IFN-a and
IFN-b. We speculate that the relatively low permissiveness of
wild-type but not IRF-3/macrophages could be due to basal
expression of ISGs (ISG54, ISG56, and/or other IRF-3 target
ISGs) and pathogen recognition molecules (RIG-I and MDA5).
Although IRF-3 had a signiﬁcant and yet largely IFN-
independent antiviral effect in myeloid cells and peripheral
tissues, it had a distinct function in neurons. IRF-3/ mice
developed higher CNS viral burden more rapidly after IC
inoculation, and theWNV-induced IFN production in IRF-3/
cortical neurons was impaired. Despite reduced expression of
several (ISG54, ISG56, RIG-I, and MDA5) host defense
molecules and lower IFN production, the absence of IRF-3
had a smaller effect on WNV replication in neurons. The
absence of basal RIG-I, MDA5, and ISG expression and less
efﬁcient IFN antiviral effector pathways could contribute to
high baseline permissiveness of cortical neurons for WNV
and perhaps other neurotropic RNA viruses. Indeed, pre-
treatment of myeloid cells with IFN-b reduced viral titer by
1,000- to 10,000-fold, but inhibited WNV infection in cortical
neurons by only 5- to 8-fold [4]. So, if IRF-3 does not
dramatically affect WNV infection in cortical neurons, why is
there increased replication in the CNS of IRF-3/ mice? We
speculate that IRF-3-dependent production of IFN-a and
IFN-b in infected cortical neurons has a paracrine antiviral
effect on other neuronal and non-neuronal (e.g., astrocytes,
oligodendrocytes, and microglia) cells in the CNS.
In summary, our experiments suggest that IRF-3 signals the
host to control viral infections and/or initiate IFN responses
by distinct mechanisms in different cell types. The differ-
ential ability to signal through IRF-3 reﬂects cell-speciﬁc
expression of pathogen recognition receptors, which alters
the baseline antiviral state of the cell and the capacity to
induce IFN responses. IRF-3-dependent basal expression of
pathogen recognition receptors and selected ISGs in speciﬁc
cell types likely expedites the induction of IFN and possibly
other cell-speciﬁc antiviral effector molecules. To this end,
genetic proﬁling studies are underway with wild-type and
deﬁcient myeloid and neuronal cells to identify novel cell-
speciﬁc antiviral pathways that inhibit WNV and other viral
infections.
Materials and Methods
Mouse experiments and quantitation of viral burden. C57BL/6
wild-type inbred mice were commercially obtained (Jackson Labo-
ratory, http://www.jax.org/). The congenic, backcrossed IRF-3/ mice
have been previously published [19] and were the generous gift of T.
Taniguchi (Tokyo, Japan). All mice were genotyped and bred in the
animal facilities of the Washington University School of Medicine,
and experiments were performed in accordance with Washington
University animal studies guidelines. Eight- to twelve-week-old mice
were used for all in vivo studies. For peripheral infection, 102 PFU of
WNV was diluted in Hanks balanced salt solution (HBSS) supple-
mented with 1% heat-inactivated fetal bovine serum (FBS) and
inoculated by footpad injection in a volume of 50 ll. IC inoculation
was performed by injecting 101 PFU of WNV diluted in 10 ll of HBSS
with 1% FBS.
Viruses. The WNV strain (3000.0259) was isolated in New York in
2000 [41] and passaged once in C6/36 cells to generate a stock virus
that was used in all experiments.
Quantiﬁcation of tissue viral burden and viremia. To monitor viral
spread in vivo, mice were infected with 102 PFU of WNV by footpad
inoculation and euthanized at days 1, 2, 4, 6, 8, and 10 after
inoculation. In some experiments, mice were infected with 101 PFU
of WNV by an intracranial route and euthanized at days 4 and 6 after
infection. After extensive cardiac perfusion with PBS, organs were
harvested, weighed, and homogenized, and virus was titrated by
standard plaque assay as previously described [42]. Viral burden also
was measured by analyzing RNA levels using ﬂuorogenic qRT-PCR as
previously described [4].
Detection of IFN activity in serum using an L929 cell bioassay.
Biologically active IFN was detected and quantiﬁed using an EMCV
L929 cytopathic effect bioassay as described previously [4]. The
percentage of protected cells was calculated as described [43],
according to the following formula: (optical density at 492 nm
[OD492] of mouse serum-treated EMCV-infected cells/ OD492 of non-
EMCV-infected cells OD492 of EMCV-infected cells/ OD492 of non-
EMCV-infected cells)3 100%).
Measurement of WNV-speciﬁc antibodies. The levels of WNV-
speciﬁc IgM and IgG were determined using an ELISA against
puriﬁed WNV E protein as described previously [44].
Quantiﬁcation of mRNA levels by qRT-PCR. Total RNA was
isolated from lymph nodes or primary cells by using the RNeasy kit
according to the manufacturer’s instructions (Qiagen, http://www.
qiagen.com/). During the isolation, to remove any contaminating
DNA, samples were treated with RNAse-free DNAse (Qiagen). mRNA
were ampliﬁed and quantiﬁed from total RNA by qRT-PCR as
previously described [9]. The following primers and probes were used
to amplify murine IFN-a, IFN-b, ISG56, and IRF-7 mRNA: IFN-a,
forward primer, 59-CTTCCACAGGATCACTGTGTACCT-39, reverse
primer, 59TTCTGCTCTGACCACCTCCC39, probe, 59-FAM-AGAGA-
GAAGAAACACAGCCCCTGTGCC-TAMRA-39; IFN-b, forward pri-
mer, 59-CTGGAGCAGCTGAATGGAAAG-39, reverse primer, 59-
CTTCTCCGTCATCTCCATAGGG-39, probe 59-FAM-CAACCT-
CACCTACAGGGCGGACTTCAAG-TAMRA-39; ISG56, forward pri-
mer, 59-GAGCCAGAAAACCCTGAGTACA-39, reverse primer, 59-
AGAAATAAAGTTGTCATCTAAATC-39, probe 59-FAM-ACTGGC-
TATGCAGTCGTAGCCTATCGCC-TAMRA-39; and IRF-7, forward
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primer, 59-CTGGAGCCATGGGTATGCA-39, reverse primer, 59-AAG-
CACAAGCCGAGACTGCT-39, probe 59-FAM-CTGGAGGGCGTG-
CAGCGTGA-TAMRA-39. To analyze the relative fold induction of
ampliﬁed mRNA, 18S rRNA expression levels were also determined
for normalization by using the Ct method as described previously
[45].
Macrophage infection. Bone marrow–derived macrophages were
generated as described previously [4]. Brieﬂy, cells were isolated from
the bone marrow of wild-type or IRF-3/mice and cultured for 7 d in
the presence of 40 ng/ml M-CSF (PeproTech, http://www.peprotech.
com/) to generate macrophages. Multi-step virus growth curves were
performed after infection at an MOI of 0.01. Supernatants were
titrated by plaque assay on BHK21–15 cells. To test for induction of
IFN-a and IFN-b and IRF-7 genes after WNV infection, 5 3 105
macrophages were infected at an MOI of 0.1. IFN mRNA was
measured by qRT-PCR as described above. To measure secreted IFN-
a and IFN-b protein levels in macrophage supernatants, a commercial
capture ELISA was used according to the manufacturer’s instructions
(PBL Biomedical Laboratories, http://www.interferonsource.com/).
Neuron infection. Primary cortical neurons were prepared from
day 15 wild-type and IRF-3/mouse embryos as previously described
[35,36]. Neurons were seeded in 24-well poly-D-lysine/laminin-coated
plates in Dulbecco’s modiﬁed Eagle’s medium (DMEM) containing
5% heat-inactivated FBS and 5% horse serum for 24 h. Cortical
neurons were then cultured for 4 d with Neurobasal medium
containing B27 and L-Glutamine (Invitrogen, http://www.invitrogen.
com/). Multi-step virus growth curves and IFN-a and IFN-b and IRF-7
gene induction and protein secretion assays were performed after
infection at an MOI of 0.001 and 0.1, respectively.
Western blots. Macrophages (106) or cortical neurons (106) were
lysed in RIPA buffer (10 mM Tris, 150 mM NaCl, 0.02% sodium azide,
1% sodium deoxycholate, 1% Triton X-100, 0.1% SDS [pH 7.4]), with
protease inhibitors (Sigma, http://www.sigmaaldrich.com/) and 1 mM
okadaic acid (Sigma). Samples (30 lg) were resolved on 10% SDS-
polyacrylamide gels. Following transfer, membranes were blocked
with 5% nonfat dried milk overnight at 4 8C. Membranes were
probed with the following panel of monoclonal or polyclonal
antibodies: anti-WNV (US Centers for Disease Control and Preven-
tion, Atlanta, Georgia, United States), anti-GAPDH (Santa Cruz
Biotechnology, http://www.scbt.com/), anti-mouse IRF-3 (Invitrogen),
anti-mouse MDA5 (Axxora, http://www.axxora.com/), and anti-mouse
ISG56 and anti-mouse ISG54 (gifts from G. Sen, Cleveland, Ohio,
United States). The RIG-I antibody was raised in rabbits using a
recombinant N-terminal fragment of RIG-I (amino acids 1–228) that
was expressed in Escherichia coli and puriﬁed by size exclusion
chromatography. Blots were incubated with peroxidase-conjugated
secondary antibodies (Jackson ImmunoResearch, http://www.
jacksonimmuno.com/) and visualized using ECL-Plus Immunoblotting
reagents (Amersham Biosciences, http://www.gelifesciences.com/).
Statistical analysis. For in vitro experiments, an unpaired t-test was
used to determine statistically signiﬁcant differences. For viral
burden analysis, differences in log titers were analyzed by the
Mann–Whitney test. Kaplan–Meier survival curves were analyzed by
the log rank test. All data were analyzed using GraphPad Prism 4
software (GraphPad Software, http://www.graphpad.com/).
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